9,344
Views
15
CrossRef citations to date
0
Altmetric
Review

Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases

, , &
Pages 594-608 | Received 17 Dec 2021, Accepted 11 Apr 2022, Published online: 28 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tony Gutschner. (2023) RNA therapeutics. RNA Biology 0:0, pages 1-2.
Read now

Articles from other publishers (14)

Matthew A. Hunt, Sara A.C. Hunt, Kelly Edinger, Joanne Steinauer & Tony L. Yaksh. (2023) Refinement of Intrathecal catheter design to enhance neuraxial distribution. Journal of Neuroscience Methods, pages 110006.
Crossref
Stine N. Hansen, Anja Holm, Sakari Kauppinen & Henrik Klitgaard. (2023) RNA therapeutics for epilepsy: An emerging modality for drug discovery. Epilepsia.
Crossref
Victoria Boock, Bhaskar Roy, Gerald Pfeffer & Virginia Kimonis. (2023) Therapeutic developments for valosin-containing protein mediated multisystem proteinopathy. Current Opinion in Neurology 36:5, pages 432-440.
Crossref
Gizem Koral, Canan Ulusoy, Judith Cossins, Konstantinos Lazaridis, Recai Türkoğlu, Yin Yao Dong, Erdem Tüzün & Vuslat Yılmaz. (2023) Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice. Journal of Neuroimmunology 383, pages 578195.
Crossref
Robyn McCartan, Olga Khorkova, Claude-Henry Volmar & Claes Wahlestedt. (2023) Nucleic acid-based therapeutics for the treatment of central nervous system disorders. Frontiers in Genetics 14.
Crossref
Harshini Kurakula, Swetha Vaishnavi, Mohammed Yaseen Sharif & Satheesh Ellipilli. (2023) Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases. ACS Omega 8:23, pages 20234-20250.
Crossref
Ningyan Hu, Eunjoo Kim, Layal Antoury & Thurman M. Wheeler. (2023) Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy. Nature Communications 14:1.
Crossref
Anisha D’Souza, Saeideh Nozohouri, Benjamin S. Bleier & Mansoor M. Amiji. (2022) CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting. Pharmaceutical Research 40:1, pages 77-105.
Crossref
Shakir Ahamad & Shahnawaz A. Bhat. (2022) The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s Disease. Journal of Medicinal Chemistry 65:24, pages 15993-16032.
Crossref
Seyed Afshin Seyednejad & Gregory C. Sartor. (2022) Noncoding RNA therapeutics for substance use disorder. Advances in Drug and Alcohol Research 2.
Crossref
Vasanti Suvarna, Kajal Deshmukh & Manikanta Murahari. (2022) miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease. Frontiers in Pharmacology 13.
Crossref
William P. Cheshire. (2022) The grand challenge of autonomic disorders. Frontiers in Neurology 13.
Crossref
Yingying Ding, Yong Zhang & Xuehong Liu. (2022) Combinational treatments of RNA interference and extracellular vesicles in the spinocerebellar ataxia. Frontiers in Molecular Neuroscience 15.
Crossref
Barbara Tedesco, Veronica Ferrari, Marta Cozzi, Marta Chierichetti, Elena Casarotto, Paola Pramaggiore, Francesco Mina, Mariarita Galbiati, Paola Rusmini, Valeria Crippa, Riccardo Cristofani & Angelo Poletti. (2022) The Role of Small Heat Shock Proteins in Protein Misfolding Associated Motoneuron Diseases. International Journal of Molecular Sciences 23:19, pages 11759.
Crossref